Motus GI released its first quarter 2019 financial results, posting a $6.3 million net loss, or a $0.29 loss per diluted share.
What you should know:
1. Motus has $15.3 million in cash and investments.
2. In the quarter, Motus submitted a 510(k) application for the second-generation Pure-Vu System. The new system improves system mobility and setup logistics.
3. Motus has several milestones it anticipates hitting in the coming quarter, including:
- Announcing the full clinical results of its Reduce study at Digestive Disease Week 2019, May 18-21 in San Diego. In initially announced results, Pure-Vu showed a statistically significant improvement in bowel cleanliness from baseline in 45 patients.
- Starting investigator-led studies centering on Pure-Vu's effectiveness for inpatient colonoscopy and high-risk outpatient colonoscopy populations
- Expanding its field-based sales and U.S. clinical resources market.
For more on Motus' milestones, click here.